A groundbreaking study reveals that a blood test can identify Alzheimer's patients at risk of rapid decline. Researchers highlight the importance of insulin resistance in accelerating cognitive impairment, opening doors for timely interventions.
In a bold move, over 90 NIH scientists have signed the Bethesda Declaration, challenging their new leader Jay Bhattacharya and the Trump administration's policies that threaten public health research and safety.
In a surprising move, the HHS has terminated a $590 million contract with Moderna for H5 avian influenza vaccine development, raising alarms among health experts amidst rising H5N1 threats.
The FDA has approved Lumipulse, the first blood test for diagnosing Alzheimer’s, offering a simpler and less invasive option compared to traditional methods like PET scans. Experts believe this could revolutionize care and research.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
A new NIH-funded study reveals crucial protein changes in spinal fluid that may provide the first specific biomarkers for frontotemporal dementia (FTD), paving the way for earlier diagnosis and treatment options.
New research reveals that HIV drugs known as NRTIs can reduce the risk of developing Alzheimer’s disease by 6% to 13% annually. Scientists urge for clinical trials to explore this promising link.
Mike Hazen, GM of the Diamondbacks, shares his personal battle with glioblastoma and the impact of the Nicole Hazen Fund for Hope during the upcoming 'Brain Tumor Awareness Night' at Chase Field. Discover how this initiative supports crucial research and helps families affected by brain cancer.
Groundbreaking research suggests that the shingles vaccine may not only prevent shingles but also significantly lower the risk of dementia in older adults. A study analyzing health records shows compelling evidence supporting this connection.
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
